Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.1x | −6.7x | −0.5x | |
PEG Ratio | 0.32 | −0.05 | 0.00 | |
Price/Book | 25.8x | 4.5x | 2.6x | |
Price / LTM Sales | 2,115.4x | 14.0x | 3.3x | |
Upside (Analyst Target) | 30.9% | 148.3% | 38.9% | |
Fair Value Upside | Unlock | −15.9% | 5.4% | Unlock |